Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company dedicated to advancing treatments for hard-to-treat hematologic diseases, has appointed Dr Monica Shaw as its new Chief Executive Officer. She succeeds Jakob Lindberg, who returns to his previous role as Chief Scientific Officer. The Board of Directors’ decision takes immediate effect.
Oncopeptides is proud to announce the appointment of a new CEO with extensive commercialization skills and experience, as the Company embarks on a transformational year. Following the granting of Marketing Authorization for Pepaxti® in the European Union, the EEA-countries, and the UK, Oncopeptides began the launch in Germany in October 2022 and has since initiated market access activities for pricing and reimbursement. With the new CEO on board, Oncopeptides is set to fully execute the commercialization and Medical Affairs activities of Pepaxti in Europe.
Dr Monica Shaw has an impressive track record of successfully commercializing more than 15 products across a wide range of therapeutic areas such as Immunology, Oncology, Virology, Neurology and Rare Diseases. She brings a wealth of executive leadership experience from the pharmaceutical industry, having held positions at GSK and LEO Pharma. With her in-depth understanding of the industry, Dr Shaw has been able to guide numerous products through phase III and onto the market.
Oncopeptides AB (publ.) is thrilled to announce the appointment of Dr Monica Shaw as the company’s new CEO. This marks a new chapter in our journey as a commercial stage biotech company and is a significant step towards providing patients access to Pepaxti. We are also grateful to have Jakob Lindberg continue his scientific engagement with Oncopeptides in the capacity of Chief Scientific Officer. This is an exciting time for Oncopeptides and we are looking forward to the future.
I am delighted to join Oncopeptides and lead the launch of Pepaxti in Europe! This is an exciting time as the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency in the UK have both granted full approval for Pepaxti. This remarkable drug provides critically important clinical value to patients with multiple myeloma, who are in desperate need of new treatment options. I am eager to work with the team to ensure that these patients can benefit from Pepaxti and get the access they need.
Oncopeptides is pleased to announce the release of new information, as required by the EU Market Abuse Regulation. This timely submission is available as of January 4, 2023, at 09:15 (CET), and provides an exciting update for those interested in the company.
Oncopeptides is a pioneering biotech company on a mission to develop therapies for difficult-to-treat hematological diseases. With its proprietary Peptide Drug Candidate platform, PDC, Oncopeptides harnesses the power of cutting-edge science to create compounds that deliver cytotoxic agents directly to cancer cells with speed and precision.
Pepaxti® (melflufen) has been granted a Marketing Authorization in the European Union, EEA-countries Iceland, Lichtenstein, and Norway, as well as in the UK, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy and have demonstrated disease progression on or after the last therapy. In the US, the drug has been granted accelerated approval under the trade name Pepaxto®, however, the FDA has recommended that the Company voluntarily withdraw the US marketing authorization for Pepaxto on December 7, 2022.
Oncopeptides, a cutting-edge biotechnology company listed on the Small Cap segment of Nasdaq Stockholm (ticker ONCO), is pushing the boundaries of modern medicine with its proprietary technology platforms and a suite of innovative new compounds.